Roche reported a 3% year-over-year decline in its Diagnostics division revenues for the first half of 2025, attributed in part to healthcare pricing reforms in China. Overall sales rose 4% to CHF 30.94 billion. Diagnostic revenues were CHF 6.96 billion, with core lab revenues down 6% and molecular lab revenues off 1%. Companion diagnostics and pathology lab revenues saw growth, up 19% and 8% respectively. Geographically, Asia Pacific diagnostic sales fell 15% at constant exchange rates, while North America and other regions experienced growth. Roche confirmed mid-single-digit sales growth guidance for full-year 2025 amid ongoing market challenges.